This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. Pfizer reaped $36.8bn from Comirnaty, the highest revenue generated from Covid-19 vaccine sales worldwide. YoY revenue growth.
Since 2015, the US Food and Drug Administration (FDA) has approved more than 450 “first generics” or the first generic equivalent for a branded drug. These medicines comprise about 10% of all genericsapproved each year.
In October, Antares Pharma licensed Ferring Pharmaceuticals’ Nocdurna® (desmopressin acetate) sublingual tablet , which was approved in 2018 for the same indication as Noctiva and has a boxed warning highlighting the same risks. Presumably, Antares’ long-established 90-person urology sales force can achieve pull-thru of this drug product.
The growing competition from genericdrugs presents challenges for the top 20 players placing pressure on drug prices. Despite a drop in sales from Regeneron’s COVID-19 antibody, REGEN-COV, due to ineffectiveness against the Omicron variant, the company experienced record US sales of $1.63 and 10%, respectively.
increase in market capitalisation over Q1 2023, fuelled by its robust portfolio of diabetes and obesity treatments – in particular, its line of glucagon-like peptide 1 receptor agonist (GLP-1) Type 2 diabetes drugs Ozempic, Rybelsus and Victoza. Novo Nordisk reported an 18.2% million by 2029.
In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors. The top 40 best-selling oncology drugs in 2023, informed by 2022 sales statistics, mark significant milestones in cancer treatment and research.
The FDAapproval of Alkermes’ new antipsychotic drug Lybalvi couldn’t have gone any better for the company, but it could still face a big challenge positioning the new drug in the highly genericised market. The post After FDAapproval, Alkermes plans soft launch for antipsychotic Lybalvi appeared first on.
If you are facing an FDA remote review, Camargo can help design a comprehensive approach in order to avoid such pitfalls. Approval of the Month: Alnylam to Use Value-Based Agreements for Ultra-rare Disease Treatment. Unapproved Drug Initiative Ends. In November, the FDA ended its Unapproved Drug Initiative.
In Par and Novartis’ agreement, Par gained exclusive rights to market its generic for six months after Novartis’ period of exclusivity finished, beginning September 30, 2014 and ending March 30, 2015. In a press release, the company said a generic launch would damage sales in FY 2023 by $300,000. Gilenya legal drama.
While the deal required regulatory divestitures, including the sale of Otezla (apremilast) to Amgen for $13.4 Blockbuster products like Botox (botulinum toxin) and Restasis (cyclosporine) provided Actavis with high-margin, branded revenue streams that complemented its existing genericdrug business.
Generic drugmaker Mylan has become the first company to secure FDAapproval for a biosimilar product that is considered completely interchangeable with the reference product – namely Sanofi’s once-daily insulin Lantus.
In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors. The top 40 best-selling oncology drugs in 2023, informed by 2022 sales statistics, mark significant milestones in cancer treatment and research.
Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. Paxlovid was first authorized under the FDA Emergency Use Authorization in December 2021 ; however, it has received FDAapproval on May 25, 2023. billion in pharmaceutical sales from 2021. billion in 2022, a 23.43
Viatris (formerly Mylan) has become the first drugmaker to win full FDAapproval for a generic version of AstraZeneca’s top-selling respiratory drug Symbicort, although launch plans remain uncertain for now. Symbicort brought in worldwide sales of $2.7 billion last year, with $1.1
Amphastar’s newly approved synthetic peptide product was determined by the FDA to be bioequivalent and therapeutically equivalent to Eli Lilly’s Glucagon Emergency Kit for Low Blood Sugar, which has a recombinant DNA (rDNA)-origin. ” According to IQVIA, the U.S.
“This first-to-market generic version of AZOPT ® (brinzolamide ophthalmic suspension) 1% in the U.S. provides patients with another important treatment option,” said Christine Baeder, SVP, Chief Operating Officer US Generics, Teva USA. Currently, one in ten generic prescriptions dispensed in the U.S.
“The launch of our first generic version of Revlimid® in the U.S. This product adds to our broad generic portfolio of oncology treatments, which accounts for 73% of the essential medicines in this category, as defined by the World Health Organization.”. Currently, 1 in 12 generic prescriptions dispensed in the U.S.
“The launch of our first-to-market authorized generic version of Epiduo® Forte Gel in the U.S. provides patients with another important treatment option,” said Christine Baeder, SVP, Chief Operating Officer US Generics, Teva USA. Currently, 1 in 11 generic prescriptions dispensed in the U.S. IMPORTANT SAFETY INFORMATION.
Teva , the generic industry has been waiting with bated breath to see whether the section viii carve-out (and thus skinny-labeled genericdrugs) will survive. Hikma , the generic industry can have some hope. Koblitz — Since the August 2021 decision in GSK v. The procedural background of Amarin v.
Teva , the generic industry has been waiting with bated breath to see whether the section viii carve-out (and thus skinny-labeled genericdrugs) will survive. Hikma , the generic industry can have some hope. Koblitz — Since the August 2021 decision in GSK v. The procedural background of Amarin v.
Adcomm splits slightly in favor of FDAapproving ChemoCentryx’s rare disease drug ( Endpoints ).
Massachusetts sues Publicis for designing ‘marketing schemes’ to boost OxyContin sales ( STAT ).
WHO approves emergency use of China’s Sinopharm Covid vaccine ( FT ).
Following the completion of the spin-off of the Upjohn Business (4) in the fourth quarter of 2020, Pfizer now operates as a focused innovative biopharmaceutical company engaged in the discovery, development, manufacturing, marketing, sales and distribution of biopharmaceutical products worldwide. Cost of Sales (1). previously $59.4
Last year, Viatris became the first company to secure FDAapproval for a biosimilar product version of Lantus – Semglee – that is completely interchangeable with the reference product, meaning it could be substituted without any prescriber intervention like a regular genericdrug.
The company said its products will cost no more than $30 per vial or $55 for five pen cartridges, adding that compares to around $329 per vial and $510 for five pens of the originator drugs. The post Insulin price caps on the horizon as Senate leader plans vote appeared first on.
While the NPRM recognizes the importance to Americans of buying more affordable drugs outside the U.S., the FDA seems to defer actions that are not only permissible but encouraged under Section 804(J) to expand access to personally imported FDA-approved and foreign versions of FDA-approveddrugs.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content